Advertisement

Topics

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

14:41 EDT 23 Aug 2017 | SCRIP

Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,969, the...

      

Related Stories

 

Original Article: The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

NEXT ARTICLE

More From BioPortfolio on "The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...